Additionally, long-term durable outcomes with Olumiant (baricitinib) in pediatric patients 12 years of age and older with severe alopecia areata will be presented from the BRAVE-AA-PEDS clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results